deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT01576328

Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

A Randomized, Placebo-Controlled Dose-Escalation Study to Assess the Safety and Tolerability of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Type 2 Diabetes Sub-optimally Controlled on Metformin

Sponsor: Mesoblast, Ltd.

Updated 8 times since 2017 Last updated: Jun 1, 2020 Started: Apr 30, 2012 Primary completion: Oct 31, 2013 Completion: Oct 31, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01576328, this PHASE1/PHASE2 trial focuses on Type 2 Diabetes and remains completed. Sponsored by Mesoblast, Ltd., it has been updated 8 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Mar 2018 · 13 months · monthly snapshotCompleted~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshotCompleted~Jun 2018 – ~Jul 2020 · 25 months · monthly snapshotCompleted~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

8 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jul 2020 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Jun 2018 — Jul 2020 [monthly]

    Completed PHASE1_PHASE2

Show 3 earlier versions
  1. Mar 2018 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

  2. Feb 2017 — Mar 2018 [monthly]

    Completed PHASE1_PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mesoblast, Ltd.
Data source: Mesoblast, Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .